

## Consent and Authorization Form

COMIRB  
APPROVED  
For Use  
31-Mar-2022  
07-Dec-2022

**Principal Investigator:** Daniel A. Pollyea, MD  
**COMIRB No:** 17-7821  
**Version Date:** 03/15/2022  
**Study Title:** *Azacitidine and Venetoclax (ABT-199) as Induction Therapy with Venetoclax Maintenance in Previously Untreated Elderly Patients with Acute Myeloid Leukemia*

---

You are being asked to participate in a research study. A member of the research team will explain what is involved in this study and how it will affect you. This consent form describes the study procedures, the risks and benefits of participation, as well as how your confidentiality will be maintained. Please take your time to ask questions and feel comfortable making a decision whether to participate or not. This process is called informed consent. If you decide to participate in this study, you will be asked to sign this form.

### **Why is this study being done?**

The purpose of this study is to learn more about a combination of two drugs and how well it might work to treat acute myeloid leukemia (AML). The two drugs are called venetoclax and azacitidine. You are being asked to be in this research study because you have been newly diagnosed with AML and are over the age of 60.

Venetoclax is approved by the U.S. Food and Drug Administration (FDA) to treat a type of leukemia called chronic lymphocytic leukemia (CLL), but is not approved to treat your specific type of cancer. Azacitidine is approved by the FDA to treat several different types of cancer, including other blood cancers, but is not approved to treat your specific type of cancer. However, azacitidine is a drug that is very commonly used to treat AML. This combination is therefore considered to be experimental.

Throughout the rest of this consent form, Venetoclax and Azacitidine will be called the “study drugs” when referenced together.

### **How many people will participate?**

Up to 70 people from your area will participate in the study.

## Consent and Authorization Form

COMIRB #17-7821  
PI: Daniel A. Pollyea, MD  
Version Date: 03/15/2022

### What happens if I join this study?

If you join the study, you will be asked to sign this consent form. You will be given a copy to keep and the original form will be kept at the clinic. You can withdraw from the study at any time and without giving a reason. This will not affect the standard medical care you receive.

There are 3 parts to the study:

1. Screening (before beginning the study drugs)
2. Induction Phase (attempt to eliminate visible leukemia in your bone marrow)
3. Maintenance Phase

If after initial therapy, you have a good response to the study drugs (no visible leukemia in your bone marrow), you may continue with the maintenance phase where you will take venetoclax daily (400mg) and stop the azacitidine, instead of continuing with azacitidine which is the standard.

If after initial therapy, you still have evidence of disease, you will continue for additional cycles in the induction phase.

The next section of this form lists what will be expected of you if you join this study.

### Study Procedures

While you are taking part in this study, some of the tests and procedures are the same type that would be performed as part of your regular cancer care even if you did not join the study. Some of the tests and procedures are required only for the study and are identified below as “**research**” procedures.

The screening tests and procedures will be done to see if you are eligible to join this study. You may have had some of these tests and procedures done recently as standard care for your cancer, and they may not need to be repeated.

- **Informed Consent**

This informed consent form will be discussed with you and you will be given a copy of this document. If you join the study, you will be asked to sign this consent form before you receive any study related tests or procedures.

- **Medical and Cancer History**

Before you start the study we will record your date of birth, race, ethnicity, and complete medical history. This history will look at the background and progress of your cancer and any treatments you have received for your disease.

## Consent and Authorization Form

COMIRB #17-7821

PI: Daniel A. Pollyea, MD

Version Date: 03/15/2022

- **Physical Examination**

A physical examination will be completed as part of your standard of care. We will also assess if the study drug is affecting your body functions including lungs, heart, abdomen, extremities, skin, head (eyes, ears, nose, hair, etc.) and neurologically.

- **Vital Signs**

We will take your blood pressure, heart rate, respiratory rate, body temperature and weight. Height will be measured only during screening.

- **Performance Status**

We will assess how well you are performing your daily activities.

- **Review of Current Medications**

Your study doctor will let you know which medications you can and cannot take while taking part in this study. From the time you first receive the study drugs through 30 days after the last dose, we will record medications you may be taking.

- **Review of Side Effects**

Some risks have been identified because of the disease process or through use of the study drugs themselves and these will be followed very closely by the Principal Investigator and study staff. More information will be provided in the Risk area of this consent.

- **Blood Collection:** Blood will be collected for routine testing over the course of the study.

- **Electrocardiogram (ECG or EKG)**

This is a simple, noninvasive procedure that records the electrical activity of the heart. Electrodes are placed on the skin of the chest and connected in a specific order to a machine. Output usually appears on a long scroll of paper that displays a printed graph.

- **Bone Marrow Biopsy/Aspirate**

At various time points during the study, you will have bone marrow examined. This involves placing a hollow needle into your hip bone near the small of your back and taking a small sample of the bone (bone marrow biopsy) and 2-3 tablespoons of the liquid bone marrow inside the bone (bone marrow aspirate). Some of the tests that will be performed on your samples are considered experimental.

## Consent and Authorization Form

COMIRB #17-7821

PI: Daniel A. Pollyea, MD

Version Date: 03/15/2022

### Study Visits

#### Screening Visit (*within 28 days before treatment*)

- Informed consent – **research**
- Review of medical history
- Complete physical exam
- Performance status
- Review of current medications
- Vital signs
- Blood draw for routine tests, including:
  - Hematology
  - Chemistry (including magnesium, phosphorus and LDH)
  - Coagulation tests (including PT and PTT/INR)
- Electrocardiogram (EKG)
- Bone marrow biopsy/aspirate (*may be performed up to 28 days prior to treatment or historical biopsies/aspirates may be acceptable, per the study doctor's discretion*)

During the induction phase, you will take azacitadine (75mg/m<sup>2</sup>) either by IV or subcutaneously on Days 1-7 of the cycle. You will take venetoclax starting on Day 1, starting at a dose of 100mg and increasing daily to 600mg by Day 4. You will continue to take venetoclax (600mg) for the rest of the cycle. Each cycle is 28 days.

#### Cycle 1 – Day -1 (*one day prior to treatment*)

- Receive pre-medications: All subjects will be admitted to the hospital about 1 day before Cycle 1 Day 1 and receive pre-medications for the study drugs.

#### Cycle 1 – Day 1 (*each cycle is 28 days*)

- Physical exam
- Performance status
- Review of side effects
- Review of current medications
- Vital signs
- Blood draw for routine tests, including:
  - Hematology
  - Chemistry (including magnesium, phosphorus and LDH)
- Receive study drug calendar and diary – **research**
- Receive pre-medications – **research**
- Receive azacitadine – **research**
- Receive venetoclax – **research**

## Consent and Authorization Form

COMIRB #17-7821

PI: Daniel A. Pollyea, MD

Version Date: 03/15/2022

### Cycle 1 – Day 2, 3, 4

- Review of side effects
- Review of current medications
- Vital signs
- Blood draw for routine tests, including:
  - Hematology
  - Chemistry (including magnesium, phosphorus and LDH) Blood collection for these tests will be done about 4 hours prior to receiving study drugs and again 6-8 hours after dosing. The post-dose blood draw is for **research** only.
- Receive pre-medications – **research**
- Receive azacitadine – **research**
- Receive venetoclax – **research**

### Cycle 1 – Day 5, 6 & 7

- Review of side effects
- Review of current medications
- Vital signs
- Blood draw for routine tests, including:
  - Hematology
  - Chemistry (including magnesium, phosphorus and LDH)
- Receive pre-medications – **research**
- Receive azacitadine – **research**
- Receive venetoclax – **research**

### Cycle 1 – Day 8

- Physical exam
- Review of side effects
- Review of current medications
- Vital signs
- Receive pre-medications – **research**
- Receive azacitadine – **research**
- Receive venetoclax – **research**
- Bone marrow aspirate – **research** (may also be performed on Day 7 after azacitadine administration)

### Cycle 1 – Day 9-27

- Receive venetoclax – **research**

## Consent and Authorization Form

COMIRB #17-7821

PI: Daniel A. Pollyea, MD

Version Date: 03/15/2022

### Cycle 1 – Day 28

- Physical exam
- Performance status
- Review of side effects
- Review of current medications
- Vital signs
- Blood draw for routine tests, including:
  - Hematology
  - Chemistry (including magnesium, phosphorus and LDH)
- Receive study calendar and study drug diary – **research**
- Receive pre-medications – **research**
- Receive venetoclax – **research**
- Collect study drug calendar and diary – **research**
- Bone marrow biopsy/aspirate – **research**

### Induction Cycles 2+

- Physical exam
- Performance status
- Review of side effects
- Review of current medications
- Vital signs
- Blood draw for routine tests, including:
  - Hematology
  - Chemistry (including magnesium, phosphorus and LDH)
- Receive study drug calendar and diary – **research**
- Receive azacitadine – **research**
- Receive venetoclax (600mg) – **research**
- Bone marrow biopsy/aspirate – **research** (Day 28 only)
- Collect study drug calendar and diary – **research** (Day 28 only)

During Induction cycles 2+, all procedures will be done on Day 1, unless otherwise indicated. Azacitadine will be given on Days 1-7 and venetoclax will be given on Days 1-28.

Bone marrow aspirate and biopsy will occur after the 2<sup>nd</sup> cycle, and if needed, the 3<sup>rd</sup> cycle. In the absence of a response after cycle 3, biopsies will occur at the study doctor's discretion but will be mandated after each odd-numbered cycle until cycle 9, after which they can be performed after every 3-6 cycles, at the study doctor's discretion.

## Consent and Authorization Form

COMIRB #17-7821

PI: Daniel A. Pollyea, MD

Version Date: 03/15/2022

### Maintenance Cycles 2+

- Physical exam
- Performance status
- Review of side effects
- Review of current medications
- Vital signs
- Blood draw for routine tests, including:
  - Hematology
  - Chemistry (including magnesium, phosphorus and LDH)
- Receive study drug calendar and diary – **research**
- Receive venetoclax (400mg) – **research**
- Bone marrow biopsy/aspirate – **research** (Day 28 only)
- Collect study drug calendar and diary – **research** (Day 28 only)

During Maintenance cycles 2+, all procedures will be done on Day 1, unless otherwise indicated. Venetoclax will be given on Days 1-28.

Bone marrow aspirate and biopsy will occur every 3 cycles for the first year, then every 6 months, or at the discretion of the study doctor.

### End of Study Visit

- Physical exam
- Performance status
- Review of side effects
- Review of current medications
- Vital signs
- Blood draw for routine tests, including:
  - Hematology
  - Chemistry (including magnesium, phosphorus and LDH)
- Bone marrow biopsy/aspirate – **research** (if aspirate & biopsy occurred within 14 days of this visit, it may not be repeated)
- Collect study drug calendar and diary – **research**

### Safety Follow-up Visit (30 days after end of treatment)

- Physical exam
- Performance status
- Review of side effects
- Review of current medications

## Consent and Authorization Form

COMIRB #17-7821

PI: Daniel A. Pollyea, MD

Version Date: 03/15/2022

The study team will continue to follow up with you at least once every three months for one year after study treatment, and then at least one time per year for 5 years as long as the study is open or until you decide to stop your participation.

### How long will I be in the study?

You may continue receiving study drugs for up to 12 cycles or until your doctor determines that you should stop receiving the study drug regimen due to side effects, progression of your disease, or until you decide to stop participating in the study.

You will be followed long term for disease status and survival information.

### What are the possible discomforts or risks?

You may have side effects while you are in this study, but you will be carefully checked by the study doctor for any problems. There may be risks or side effects of the study treatment that are unknown at this time. You should tell the study doctor about anything that is bothering you or any side effects you have, even if you do not think they are related to the study treatment. Many side effects go away shortly after the medications are stopped, but in some cases side effects can be serious, long lasting, or may never go away.

### Risks of the Study Drugs

Venetoclax, either alone or in combination with other agents, has been associated with nausea, diarrhea, decreases in lymphocytes and neutrophils (two different types of white blood cells), potential decreases in sperm numbers, tumor lysis syndrome (TLS) and infections.

Venetoclax decreases the number of white blood cells in the blood. Having decreased numbers of white blood cells may be associated with fever and may increase your risk of infection including serious infections that may lead to **death**. When treatment with venetoclax is given with other cancer drugs, the risk of this may be higher. If you notice fever or other symptoms of infection, notify your doctor or nurse right away.

Anemia (low levels of red blood cells that carry oxygen throughout your body) may occur while taking venetoclax. When treatment with venetoclax is given with other cancer drugs, the risk of anemia may be higher. You may experience weakness or fatigue. If you notice this, notify your doctor. Your study doctor will take regular blood tests to monitor for these changes. You may require blood transfusion.

Decreases in platelets (type of cells which help prevent bleeding) can occur while taking venetoclax. When treatment with venetoclax is given with other cancer drugs, the risk of decrease in platelets may be higher. If you notice any bruising or bleeding, notify your



## Consent and Authorization Form

COMIRB #17-7821

PI: Daniel A. Pollyea, MD

Version Date: 03/15/2022

doctor. Your study doctor will take regular blood tests to monitor for these changes. You may require platelet transfusion.

Do not eat the following citrus fruits for up to 3 days prior to the first dose of venetoclax and throughout your participation in the study:

- Grapefruit or grapefruit products
- Seville oranges (including marmalade containing Seville oranges)
- Star fruit (carambola)

Also, let the physician know all your current medications and supplements you are taking.

### ***Risk of Tumor Lysis Syndrome***

Tumor lysis syndrome (TLS) is a problem that can occur when cancer cells break down rapidly and the body has to get rid of the broken up cell parts. Sometimes your body, especially the kidneys, can't remove the cell parts quickly enough, so the level of some of these cell products in your blood, such as salts and acids, can rise. This can happen especially in subjects with large tumors or a high number of cancerous white cells in the blood. Tumor lysis syndrome is most likely to occur in the first 5 weeks of starting venetoclax.

Tumor lysis syndrome can lead to serious problems, such as effects on your kidneys, heart (including abnormal heart rhythms), brain, or seizures. These side effects can result in needing kidney dialysis (a special machine to remove toxins from the blood) or lead to **death**. If you develop TLS, your study doctor will closely monitor and treat you as needed to try to prevent these complications.

Blood tests have shown TLS in some participants after receiving the initial dose of venetoclax or after receiving a higher dose of venetoclax than previously received. Two deaths in participants with chronic lymphocytic leukemia (CLL) who experienced TLS have been reported after receiving venetoclax, and 1 CLL participant with TLS has needed dialysis.

To reduce the risk of developing TLS, your study doctor will hospitalize you before you start venetoclax to give fluids into your vein, do blood tests, and check for TLS. You will begin treatment with venetoclax at a low dose. Your study doctor will gradually increase the dose to the full standard dose. If you develop TLS, your urine may look dark, thick, or cloudy. You may experience fever, chills, nausea (feeling sick to your stomach), vomiting, diarrhea, confusion, shortness of breath, irregular heartbeat, unusual tiredness, muscle pain, joint discomfort and/or seizure. If you notice any of these, notify your doctor or nurse right away.

## Consent and Authorization Form

COMIRB #17-7821

PI: Daniel A. Pollyea, MD

Version Date: 03/15/2022

Your study doctor will closely monitor and treat you as needed to decrease the risk of any serious changes in your blood or other complications of TLS. If blood tests suggesting TLS are seen, extra blood tests or monitoring of your heart rhythm may be recommended by your study doctor.

### ***Serious Infections***

Infections, including serious infections and some infections leading to death, have been reported in patients taking venetoclax. Your doctor may advise you to take medicines to help prevent some common infections for which you may be at risk. Your doctor may also advise you to take other measures to reduce your chance of developing an infection. If you notice fever or other symptoms of infection, notify your doctor or nurse right away.

### ***Other cancers***

Some patients who have received several previous chemotherapy treatments may develop another cancer. It is unknown if venetoclax has contributed since these types of cancers can happen in people who have not received venetoclax.

### ***Side Effects Associated with Venetoclax***

**Very common** (affects more than 1 in 10 people)

- Upper respiratory tract infection – signs include runny nose, sore throat, or cough
- Pneumonia
- Low number of white blood cells (neutrophils), sometimes with fever. A decreased number of white blood cells may increase your risk of infection including serious infections that may lead to **death**.
- Diarrhea
- Nausea or vomiting
- Constipation
- Feeling tired
- Low number of red blood cells (anemia). A decreased number of red blood cells may result in weakness and fatigue. In severe cases, a blood transfusion may be necessary.
- A decrease in platelets in your blood can increase bleeding and bruising (thrombocytopenia)
- Abdominal Pain
- Blood bilirubin increase
- Weight decrease
- Decreased appetite
- Lower level of potassium (hypokalaemia)
- Joint Pain (arthralgia)

## Consent and Authorization Form

COMIRB #17-7821

PI: Daniel A. Pollyea, MD

Version Date: 03/15/2022

- Dizziness/Fainting (syncope)
- Headache
- Shortness of breath (dyspnea)
- Bleeding (hemorrhages), with the most common events being: nose bleeds (epistaxis), bruising (contusions), and tiny round spots on skin (petechiae)
- Low blood pressure (hypotension)

**Common** (affects 1 in 100 people up to 1 in 10 people)

- Urinary tract infection
- Very serious infection in your blood caused by a bacteria (sepsis)
- Low number of lymphocytes (another type of white blood cell). A decreased number of white blood cells may increase your risk of infection including serious infections that may lead to **death**.
- Tumor lysis syndrome (described above; may experience fever, chills, nausea (feeling sick to your stomach), vomiting, diarrhea, confusion, shortness of breath, irregular heartbeat, unusual tiredness, muscle pain, joint discomfort and/or seizure.)
- Higher level of phosphorous (hyperphosphatemia)
- Higher level of uric acid/urate (hyperuricemia)
- Higher level of potassium (hyperkalemia)
- Lower level of calcium (hypocalcemia)
- Higher level of creatinine (blood creatinine increase)
- Swelling, redness, and pain of the mouth (stomatitis)
- Feeling of weakness or lack of energy (asthenia)
- Painful swelling of the gallbladder, which may be caused by gallstones blocking the flow of bile (Cholecystitis/Cholelithiasis)

Venetoclax may be given at the same time as other cancer drugs. If venetoclax and the other cancer drugs have the same side effects, the risk of those side effects may be higher than when venetoclax is given alone.

### ***Side Effects Associated with Azacitidine***

**Common or very common** (may affect more than 1 in 100 people):

- Decrease in your platelets (thrombocytopenia)
- Decrease in red blood cells (anemia)
- Decrease in white blood cells (leukopenia)
- Decrease in a type of white blood cells called neutrophils (neutropenia)
- Fever with low number of a type of white blood cell called neutrophils (febrile neutropenia)
- Bone marrow failure
- Neutropenia with infection and the presence of bacteria in your blood stream (neutropenic sepsis)

## Consent and Authorization Form

COMIRB #17-7821

PI: Daniel A. Pollyea, MD

Version Date: 03/15/2022

- Bacteria or viral infections including lung infection (pneumonia), upper respiratory infection, or urinary tract infection
- Fever
- Bleeding including brain and stomach/gut bleeding
- Bruising
- Injection site pain, redness, or bruising (if receiving azacitidine as an injection under the skin)
- Kidney failure
- Abdominal pain
- Constipation
- Diarrhea
- Feeling sick to your stomach (nausea)
- Vomiting
- Chest pain
- Shortness of breath
- Feeling tired or lethargic
- Lack of appetite or interest in food
- Weight loss
- Pain including joint, muscle pain and headache
- Dizziness
- Anxiety and difficulty sleeping
- Rash
- Itching
- Decrease in blood potassium

The following events have been reported in trials with azacitidine less frequently, but can be severe in nature. These events may or may not be related to azacitidine.

- Severe or fatal infections including severe skin infections (necrotizing fasciitis)
- Severe bleeding
- Heart problems: Cardiac arrest (heart stopped), heart attack, irregular heart beat
- Liver damage in individuals with previous liver problems Severe allergic reactions (anaphylaxis)
- Tumor lysis syndrome

If you will receive combination treatment, additional risks, warnings, and precautions, as outlined should be discussed with your study doctor. You should contact the study doctor or study staff and get medical help if you have any of the above mentioned or any other side effects during the study. Combination of azacitidine with venetoclax may worsen the potential side effects of azacitidine or venetoclax, or even cause other side effects that were not known before.

## Consent and Authorization Form

COMIRB #17-7821  
PI: Daniel A. Pollyea, MD  
Version Date: 03/15/2022

### **Risks of the Study Procedures**

#### ***Blood tests***

Blood sampling and needle punctures carry some risk. Possible side effects include, but are not limited to, fainting, bleeding, bruising, discomfort, dizziness, infection and/ or pain at the puncture site.

#### ***Having an IV inserted in your vein***

In this study we will insert a needle, connected to a plastic tube, into a vein in your arm. We will use the tube to take blood samples or give you fluids. You will feel some pain when we first insert the tube into your vein. You may have some redness, swelling, or bruising where the tube goes under your skin. In some cases, this type of tube can cause an infection where it goes under the skin. In rare cases, it can cause a blood clot in the vein. You will have this tube inserted for about four or five hours.

#### ***Bone marrow biopsy***

In this study we will take four samples of bone marrow from your pelvic bone. Before we take each sample, we will give you some numbing medication on the skin outside your pelvic bone (on your hip). After your skin is numb, we will push a special needle into the center of your pelvic bone. Then, we will draw the bone marrow up into the syringe. When we do this, you will have a pulling feeling as the marrow leaves the bone and goes into the syringe. The area around the bone will be sore for a few days.

There is a very small chance that you will be allergic to the numbing medicine. There is also a very small chance that you could bleed or develop an infection.

#### ***Electrocardiogram (EKG)***

An electrocardiogram (EKG) is a test that records the electrical activity of the heart. Skin irritation is rare but could occur during an EKG from the electrodes or the gel that is used.

### **Risks Associated with Pregnancy**

When pregnant animals were dosed with venetoclax, decreased weight or premature loss of the developing baby was observed. It is unknown if any of the effects seen in animals will occur in humans. While participating in this research study, you should not become pregnant, nurse a baby, or father a baby. Both men and women who are able to have children must use a highly effective means of birth control approved by your study doctor. You must continue the use of birth control during the entire time of your study participation and to at least 30 days after the last dose of venetoclax or at least 3 months after the last dose of azacitidine.

If you are a female who has stopped having menstrual periods for at least 1 year (menopause), please discuss with your study doctor the need for birth control. If you become pregnant, you must stop taking venetoclax at once and notify your doctor

## Consent and Authorization Form

COMIRB #17-7821

PI: Daniel A. Pollyea, MD

Version Date: 03/15/2022

immediately. You will not be allowed to continue in the study. You may be asked questions about the outcome of your pregnancy and the baby.

If you are a male, venetoclax may decrease your ability to produce sperm. You may wish to consider banking your sperm before beginning treatment. In addition, you are responsible for informing your partner(s) that the effects of venetoclax on an unborn fetus or embryo in humans are unknown. You and your partner(s) are responsible for using acceptable birth control as described above. Discuss with your partner acceptable forms of contraception. If your partner becomes pregnant while you are on study, you must notify your doctor immediately. You and your partner may be asked questions about the outcome of the pregnancy and the baby. Written informed consent for release of medical information from your partner will be obtained prior to collecting any information about the pregnancy and baby.

### **Risk of Loss of Confidentiality**

There is a risk that people outside the research team will see your research information. We will do all that we can to protect your information, but it cannot be guaranteed.

There may be other risks that could arise which are not reasonably foreseeable. If new information becomes available which could influence your willingness to continue, this new information will be discussed with you.

### **What are the possible benefits of the study?**

If you agree to take part in this study, there may or may not be direct medical benefit to you. We hope the information learned from this study will benefit other individuals with AML in the future.

### **Are there alternative treatments?**

There may be other ways of treating your cancer. Instead of taking part in this study:

- You may choose to receive treatment with an approved therapy.
- You may choose to participate in a different study with another experimental drug.
- You may choose to receive comfort/ palliative care.
- You may choose to get no treatment at all.

You should talk to your doctor about your choices. Make sure you understand all of your choices before you decide to take part in this study. You may leave this study and still have these other choices available to you.

## **Consent and Authorization Form**

**COMIRB #17-7821**

**PI:** Daniel A. Pollyea, MD

**Version Date:** 03/15/2022

### **Who is paying for this study?**

AbbVie, Inc. is providing a grant of funding support for this study. AbbVie manufactures the study drug, venetoclax, and will provide this drug for the study. This research is being conducted by Dr. Daniel Pollyea. The research study will only pay for procedures not considered standard of care.

Two of the investigators on this study, Dr. Pollyea and Dr. Smith, have a financial interest with AbbVie, Inc., as they are consultants for the company. AbbVie, Inc is the manufacturer of venetoclax. Please feel free to ask any questions you may have about this matter.

### **Will I be paid for being in the study?**

You will not be paid to be in the study.

### **Will I have to pay for anything?**

The drug manufacturer, AbbVie, will pay for the cost of the study drug, venetoclax. The funding for this study will also pay for any tests or procedures that are related to the research study.

The study drug, azacitadine, is considered standard treatment for your type of cancer. This drug will be obtained through your insurance, and you will be responsible for any applicable copays required by your insurance policy.

There are some medical procedures that you would get for your condition whether you were in this study or not, such as blood draws. These are considered standard of care. You and/or your health insurance may be billed for the costs of medical care during this study, if these expenses are related to standard of care procedures. If you have health insurance, the cost of these services will be billed to your insurance company. If your insurance does not cover these costs, or you do not have insurance, these costs will be your responsibility.

Ask your study doctor to discuss the costs that will or will not be covered by this research study. This discussion should include the costs of treating possible side effect. Otherwise, you might have unexpected expenses from being in this study.

### **Is my participation voluntary?**

Taking part in this study is voluntary. You have the right to choose not to take part in this study. If you choose to take part, you have the right to stop at any time. If you refuse or decide to withdraw later, you will not lose any benefits or rights to which you are entitled.

## **Consent and Authorization Form**

**COMIRB #17-7821**

**PI:** Daniel A. Pollyea, MD

**Version Date:** 03/15/2022

If you leave this study, you will still receive your normal medical care. The only medical care that you will lose is the medical care you are getting as part of this study. You might be able to get that same kind of medical care outside of the study. Ask your study doctor.

### **Can I be removed from this study?**

The study doctor may decide to stop your participation without your permission if the study doctor thinks that being in the study may cause you harm, or for any other reason.

### **What happens if I am injured or hurt during the study?**

If you have an injury while you are in this study, you should call Dr. Pollyea immediately. His phone number is 720-848-8084.

We will arrange to get you medical care if you have an injury that is caused by this research. However, you or your insurance company will have to pay for that care.

### **Who do I call if I have questions?**

The researcher carrying out this study is Daniel A. Pollyea, MD. You may ask any questions you have now. If you have questions, concerns, or complaints later, you may call Dr. Pollyea at 720-848-8084. You will be given a copy of this form to keep.

You may have questions about your rights as someone in this study. You can call Dr. Pollyea with questions. You can also call the responsible Institutional Review Board (COMIRB). You can call them at 303-724-1055.

A description of this clinical trial will be available on <http://www.ClinicalTrials.gov>, as required by U.S. Law. This Web site will not include information that can identify you. At most, the Web site will include a summary of the results. You can search this Web site at any time.

### **Who will see my research information?**

The University of Colorado Denver (UCD) and its affiliated hospital(s) have rules to protect information about you. Federal and state laws including the Health Insurance Portability and Accountability Act (HIPAA) also protect your privacy. This part of the consent form tells you what information about you may be collected in this study and who might see or use it.

The institutions involved in this study include:

- University of Colorado Denver
- University of Colorado Hospital

We cannot do this study without your permission to see, use and give out your information. You do not have to give us this permission. If you do not, then you may not join this study.



## Consent and Authorization Form

**COMIRB #17-7821**

**PI:** Daniel A. Pollyea, MD

**Version Date:** 03/15/2022

We will see, use and disclose your information only as described in this form and in our Notice of Privacy Practices; however, people outside the UCD and its affiliate hospitals may not be covered by this obligation.

We will do everything we can to maintain the confidentiality of your personal information but confidentiality cannot be guaranteed.

The use and disclosure of your information has no time limit. You can cancel your permission to use and disclose your information at any time by writing to the study's Principal Investigator (PI), at the name and address listed below. If you do cancel your permission to use and disclose your information, your part in this study will end and no further information about you will be collected. Your cancellation would not affect information already collected in this study.

Daniel A. Pollyea, MD  
Anschutz Medical Campus  
1665 N. Aurora Court  
Mail Stop F754  
Aurora, CO 80045

Both the research records that identify you and the consent form signed by you may be looked at by others who have a legal right to see that information, such as:

- Federal offices such as the Food and Drug Administration (FDA) and the Office of Human Research Protections (OHRP) that protect research subjects like you.
- People at the Colorado Multiple Institutional Review Board (COMIRB).
- The study doctor and the rest of the study team.
- AbbVie, Inc., manufacturer of venetoclax who is also providing a grant of funding support.
- Officials at the institution where the research is conducted and officials at other institutions involved in this study who are in charge of making sure that we follow all of the rules for research.

We might talk about this research study at meetings. We might also print the results of this research study in relevant journals. But we will always keep the names of the research subjects, like you, private.

You have the right to request access to your personal health information from the Investigator.

## **Consent and Authorization Form**

**COMIRB #17-7821**

**PI: Daniel A. Pollyea, MD**

**Version Date: 03/15/2022**

### **Information about you that will be seen, collected, used and disclosed in this study:**

- Name and demographic information (age, sex, ethnicity, address, phone number, etc.
- Portions of your previous and current medical records that are relevant to this study, including but not limited to diagnosis(es), history and physical, laboratory or tissue studies, radiology studies, procedure results.
- Research visit and research test records.
- Tissue samples and the data with the samples.
- Billing or financial information.

### **What happens to Data, Tissue, Blood and Specimens that are collected in this study?**

Scientists at the University of Colorado Denver and the hospitals involved in this study work to find the causes and cures of disease. The data, tissue, blood and specimens collected from you during this study are important to this study and to future research. If you join this study:

- The data, tissue, blood, or other specimens given by you to the investigators for this research no longer belong to you.
- Both the investigators and any sponsor of this research may study your data, tissue, blood, or other specimens collected from you.
- If data, tissue, blood, or other specimens are in a form that identifies you, UCD or the hospitals involved in this study may use them for future research only with your consent or Institutional Review Board (IRB) approval.
- Any product or idea created by the researchers working on this study will not belong to you.
- There is no plan for you to receive any financial benefit from the creation, use or sale of such a product or idea.

### **Agreement to be in this study and use my data**

The research project and the procedures associated with it have been explained to me. The experimental procedures have been identified and no guarantee has been given about the possible results. I will receive a signed copy of this consent form for my records.

I agree to participate in this study. My participation is voluntary and I do not have to sign this form if I do not want to be part of this research study.

## Consent and Authorization Form

COMIRB #17-7821  
PI: Daniel A. Pollyea, MD  
Version Date: 03/15/2022

Subject Signature: \_\_\_\_\_

Date: \_\_\_\_\_

Subject Print Name: \_\_\_\_\_

Consent form explained by: \_\_\_\_\_

Date: \_\_\_\_\_

Print Name: \_\_\_\_\_

----- **Use Only if Applicable** -----

*Signature Line for witness; required for consent of non-reading subjects and consent using a short form, if you requested such consent procedures*

Witness of Signature ☐

Witness of consent process ☐

Witness Signature: \_\_\_\_\_

Date: \_\_\_\_\_

Witness Print Name: \_\_\_\_\_